Becton, Dickinson and Company (NYSE:BDX) Releases FY 2025 Earnings Guidance

Becton, Dickinson and Company (NYSE:BDX) updated its FY 2025 earnings guidance on Wednesday. The company provided earnings per share (EPS) guidance of 14.300-14.600 for the period, compared to the consensus estimate of 14.350. The company issued revenue guidance of $21.7 billion-$21.9 billion, compared to the consensus revenue estimate of $21.9 billion.

Analyst Ratings Changes

Several analysts have recently commented on BDX shares. Piper Sandler increased their target price on Becton, Dickinson and Company from $275.00 to $280.00 and gave the stock an “overweight” rating in a report on Tuesday, January 28th. StockNews.com cut shares of Becton, Dickinson and Company from a “buy” rating to a “hold” rating in a research note on Wednesday, December 18th. One equities research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company. Based on data from MarketBeat, Becton, Dickinson and Company currently has a consensus rating of “Moderate Buy” and a consensus price target of $283.00.

Becton, Dickinson and Company Stock Down 4.5 %

NYSE:BDX traded down $11.03 on Thursday, hitting $234.03. 1,754,869 shares of the company’s stock were exchanged, compared to its average volume of 2,029,463. Becton, Dickinson and Company has a 52 week low of $218.75 and a 52 week high of $251.99. The company has a market cap of $67.87 billion, a P/E ratio of 39.43, a price-to-earnings-growth ratio of 1.80 and a beta of 0.40. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.17 and a quick ratio of 0.74. The firm has a 50-day moving average price of $231.79 and a 200-day moving average price of $234.09.

Becton, Dickinson and Company (NYSE:BDX) last announced its earnings results on Wednesday, February 5th. The medical instruments supplier reported $3.43 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.00 by $0.43. Becton, Dickinson and Company had a net margin of 8.55% and a return on equity of 14.89%. As a group, analysts expect that Becton, Dickinson and Company will post 14.41 EPS for the current fiscal year.

Becton, Dickinson and Company Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Monday, March 31st. Investors of record on Monday, March 10th will be given a dividend of $1.04 per share. This represents a $4.16 dividend on an annualized basis and a yield of 1.78%. The ex-dividend date of this dividend is Monday, March 10th. Becton, Dickinson and Company’s dividend payout ratio is 70.03%.

Becton, Dickinson and Company declared that its board has initiated a stock buyback plan on Tuesday, January 28th that allows the company to buyback 10,000,000 shares. This buyback authorization allows the medical instruments supplier to reacquire shares of its stock through open market purchases. Shares buyback plans are typically a sign that the company’s board believes its shares are undervalued.

Insider Buying and Selling at Becton, Dickinson and Company

In other news, EVP David Shan sold 500 shares of the company’s stock in a transaction that occurred on Tuesday, January 21st. The stock was sold at an average price of $240.00, for a total transaction of $120,000.00. Following the transaction, the executive vice president now directly owns 5,741 shares of the company’s stock, valued at $1,377,840. This represents a 8.01 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, EVP Shana Carol Neal sold 788 shares of the stock in a transaction dated Tuesday, January 7th. The shares were sold at an average price of $235.00, for a total transaction of $185,180.00. Following the completion of the sale, the executive vice president now owns 16,201 shares of the company’s stock, valued at approximately $3,807,235. This represents a 4.64 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 9,844 shares of company stock worth $2,210,716. Insiders own 0.36% of the company’s stock.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.